UK – Gov signs deals with BioNTech/Pfizer and Valneva for COVID vaccines

The government has signed new deals with BioNTech/Pfizer and Valneva for access to 90 million doses of experimental COVID-19 vaccines.

Through its partnership with Valneva, for 60 million doses of its inactivated whole virus vaccine VLA2001, the government is expected to contribute to UK clinical studies costs and is negotiating funding to expand the firm’s Scottish facility.

This increased manufacturing capacity could potentially supply up to 100 million vaccine doses to the UK and internationally, and will create high-skilled jobs in the local area.

Its deal with BioNTech and Pfizer, which are developing mRNA-based vaccines BNT162b1 and BNT162b2, sees 30 million doses of vaccine destined for UK shores.

In a separate deal with AZ, it has also secured access to one million doses of a treatment containing COVID-19-neutralising antibodies to protect those who cannot receive vaccines such as cancer and immunocompromised patients…